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Abstract
Introduction Disturbed alveolar fibrin turnover is a cardinal
feature of severe pneumonia. Clinical studies suggest that
natural inhibitors of coagulation exert lung-protective effects via
anticoagulant and possibly also anti-inflammatory pathways.
Intravenous infusion of the natural anticoagulants increases the
risk of bleeding. Local administration may allow for higher
treatment dosages and increased local efficacy while at the
same time reducing the risk of bleeding. We evaluated the effect
of nebulized anticoagulants on pulmonary coagulopathy and
inflammation in a rat model of Streptococcus pneumoniae
pneumonia.
Methods In this randomized controlled in vivo laboratory study
rats were challenged intratracheally with S. pneumoniae,
inducing pneumonia, and randomized to treatment with normal
saline (placebo), recombinant human activated protein C (rh-
APC), plasma-derived antithrombin (AT), heparin or danaparoid,
by means of nebulization.
Results S. pneumoniae infection increased pulmonary levels of
thrombin-antithrombin complexes and fibrin degradation
products. All nebulized anticoagulants significantly limited
pulmonary coagulopathy. None of the agents except danaparoid
resulted in changes in systemic coagulopathy. Treatment with
plasma-derived AT reduced outgrowth of S. pneumoniae and
histopathologic damage in lungs. In vitro experiments confirmed
outgrowth was reduced in bronchoalveolar lavage fluid (BALF)
from rats treated with plasma-derived AT compared with
placebo. Neutralizing of cationic components in BALF
diminished the inhibitory effects on bacterial outgrowth of BALF,
suggesting a role for cationic antimicrobial proteins.
Conclusions Nebulization of anticoagulants attenuates
pulmonary coagulopathy during S. pneumoniae pneumonia in
rats while only danaparoid affects systemic coagulation.
Nebulized plasma-derived AT reduces bacterial outgrowth and
exerts significant lung-protective effects.
Introduction
Pulmonary coagulopathy is a hallmark of pneumonia [1-4] and
other forms of acute lung injury [2,5,6]. Excessive fibrin depo-
sition within the airways, as a result of activation of coagulationPage 1 of 10
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and function [7,8]. Infusion of recombinant human activated
protein C (rh-aPC), one of the natural inhibitors of coagulation,
has been shown to benefit patients with severe sepsis or sep-
tic shock [9]. Of interest, rh-aPC treatment lead to a more
rapid resolution of respiratory failure [9]. In addition, patients
with pneumonia as the source of sepsis benefited most from
treatment with rh-aPC [10]. Consequently, it has been sug-
gested that anticoagulant and anti-inflammatory effects of rh-
aPC in the lungs contribute to better outcome [11,12]. In a
recent study in patients with acute lung injury (ALI), systemic
rh-aPC treatment did not affect ventilator-free days [13]. How-
ever, due to the low number of patients the statistical power to
detect a difference in the primary endpoint was limited. Lung-
protective effects of antithrombin (AT), another natural inhibi-
tor of coagulation have been demonstrated in a relatively lim-
ited number of patients with sepsis [14]. AT did not affect
mortality in patients with sepsis in a larger phase III clinical trial
but no subgroup analysis on patients with pneumonia as the
primary source of sepsis was performed [15]. Heparin is a
potent activator of AT and has been used in several preclinical
studies to prevent fibrin deposition in models of ALI [2-4]. In a
recent study, continuous infusion of low-dose unfractionated
heparin did not affect mortality in patients with sepsis [16], nor
was mortality affected in a subgroup of patients with pneumo-
nia. However, no subgroup analysis was performed on
patients with respiratory failure or ALI/acute respiratory dis-
tress syndrome (ARDS).
We recently demonstrated that systemic anticoagulant treat-
ment attenuates pulmonary coagulopathy in pneumonia
caused by Streptococcus pneumoniae in rats [1]. Intrave-
nously administered rh-aPC, plasma-derived AT or heparin
attenuated pulmonary coagulopathy. AT, but not rh-aPC and
heparin, exerted significant lung-protective effects in this
model. Systemically administered rh-aPC, AT and heparin also
attenuated systemic coagulation, which can be considered a
major drawback because of increased risks of severe bleed-
ing. We hypothesized local treatment to be equally effective as
systemic treatment in attenuating pulmonary procoagulant
changes while leaving systemic coagulation unaltered. In addi-
tion, we hypothesized that there are beneficial anti-bacterial
and anti-inflammatory effects of locally administered plasma-
derived AT, as was seen with intravenous administration of this
anticoagulant in this model.
Materials and methods
The Institutional Animal Care and Use Committee of the Aca-
demic Medical Center approved all experiments. All animals
were handled in accordance with the guidelines prescribed by
the Dutch legislation and the International Guidelines on pro-
tection, care, and handling of laboratory animals.
Animals
Pneumonia was induced in male Sprague-Dawley rats (weigh-
ing 250 to 300 g; Harlan, Horst, The Netherlands) by intratra-
cheal instillation of 5 × 106 colony-forming units (CFU) of S.
pneumoniae (serotype 3, ATCC 6303) as described previ-
ously [1].
Anticoagulant strategies
Rats were randomized to placebo (normal saline) or treatment
with 5000 μg/kg rh-aPC (drotrecogin alfa (activated), Eli Lilly,
Indianapolis, IN, USA), 500 units/kg plasma-derived AT
(plasma-derived AT III, Baxter, Vienna, Austria), 1000 IU/kg
heparin (Leo Pharmaceutical, Ballerup Denmark) or 250 anti-
Xa E/kg danaparoid (Orgaran, Organon, Oss, the Nether-
lands; n = 7 per group). Healthy animals without pneumonia
served as controls (n = 4). Dosages and timing of study med-
ication were determined using data from previous studies
[1,17-19]; the first administration of each agent was 30 min-
utes before bacterial challenge. Considering its longer elimina-
tion half-life (19 to 72 hours [20]) nebulization of AT was
repeated every 24 hours; nebulization of saline, rh-aPC (elimi-
nation half-life 45 minutes), heparin (elimination half-life
approximately 1.5 hours) and danaparoid (elimination half-life
25 hours) was repeated every six hours until sacrifice.
For local administration of saline or study medication we used
an exposure system which allows direct exposure of nebulized
agents to the noses of the animals. This system consisted of a
concentric manifold connected to the necks of bottle-like
restraint tubes (CHT 249 restraint tube, CH technologies Inc.,
Westwood, NJ, USA) in which the animals were confined with
their noses adjacent to the bottle necks. The bottles were
detachable and the device could be disassembled (e.g., for
cleaning) by removing the bottles and removing the manifold.
The inhalation chamber was suitable to accommodate several
rats at once. One extra outlet was available for measuring the
pressure and atmosphere sampling inside the inhalation
chamber. The aerosolized agent was supplied to the upper
end of the manifold, flows adjacent to the noses of the individ-
ual animals, and then was drawn out through the bottom of the
manifold. The aerosol atmosphere was generated using the
AeronebPro Micropump Nebulizer (Aerogen Ltd., Galway, Ire-
land). The aerosols were directed to the inhalation chamber by
a constant oxygen flow (2 L/min).
Measurements
At 40 hours after challenge with S. pneumoniae, rats were
sacrificed and blood samples, bronchoalveolar lavage fluid
(BALF) and lung tissue were obtained and analyzed as
described previously [1]. For bacterial quantification, BALF
and whole blood were plated onto sheep-blood agar plates.
Thrombin-antithrombin complexes (TATc; Behring, Marburg,
Germany) and fibrin degradation products (FDP; Asser-
achrom D-Di, Diagnostica Stago, Asnières-sur-Seine, France)
were measured in BALF using ELISA. AT, plasminogenPage 2 of 10
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(PAI)-1 activity were measured by automated amidolytic
assays [21]. Levels of TNF-α, IL-6 and cytokine-induced neu-
trophil chemoattractant (CINC)-3 (R&D Systems, Abingdon,
UK) and myeloperoxidase (MPO) (HyCult biotechnology b.v.,
Uden, The Netherlands) were measured using ELISA in lung
homogenates.
Lung histopathology
Histopathology was analyzed and scored by two investigators
who were blinded for group identity. Four micrometer sections
were stained with hematoxylin and eosin, and analyzed by two
researchers blinded for group identity. To score lung inflamma-
tion and damage, the entire lung surface was analyzed with
respect to the following variables: interstitial inflammation,
endothelialitis, bronchitis, edema, pleuritis, and thrombus for-
mation, as described previously [22]. Each variable was
graded on a scale of 0 to 4 (0, absent; 1, mild; 2, moderate; 3,
severe; 4, very severe). The total histopathology score was
expressed as the sum of the scores for all variables.
In vitro studies on the antimicrobial effects of plasma-
derived AT
For further analysis of the potential antimicrobial effect of
plasma-derived AT we compared cell-free supernatants from
BALF of infected animals which were treated with AT (BALF-
AT) with BALF from infected placebo-treated rats (BALF-
none).
To assess the antimicrobial effect of BALF-AT and BALF-none
samples, these samples were added to inoculum suspension
and incubated. To assess direct antibacterial activity of
plasma-derived AT, inoculum suspension was added to dilu-
tions of plasma-derived AT in phosphate-buffered tryptic soy
broth (TSB) medium and incubated.
Innate host immune responses can lead to the expression of
cationic antimicrobial peptides (e.g., defensins) [23]. Such
peptides can be inhibited by nonspecific binding to negatively
charged molecules. We hypothesized plasma-derived AT
administration to lead to lower levels of coagulation/inflamma-
tion, and therefore to lower concentrations of extracellular pro-
tein and coagulation products in the lung, and hence, to less
inhibition of cationic antimicrobial peptides. To test whether
plasma-derived AT treatment leads to less inhibition of cationic
antimicrobial peptides inoculum suspensions were incubated
with BALF-AT with or without sodium polyanetholsulphonate
(SPS).
Statistical analysis
All in vivo data are expressed as mean ± standard deviation or
median with interquartile ranges, as appropriate. Comparisons
between the experimental groups and the saline-treated pla-
cebo group were performed using one-way analysis of vari-
ance (ANOVA) or Kruskal-Wallis test, followed by post-hoc
Dunnett's or Dunn's tests, depending on data distribution. A P
value less than 0.05 was considered statistically significant.
The in vitro data was log-transformed. Then a one-way
ANOVA was performed for separate time points to determine
the significance of the difference in growth followed by Bon-
ferroni post-testing. Statistical analyses were performed with
SPSS 16.0 (SPSS, Chicago, IL, USA) and Prism 4.0 (Graph-
Pad Software, San Diego, CA, USA).
Results
Pneumonia
After instillation of S. pneumoniae, typical clinical symptoms of
illness (pilo-erection, decreased activity, arched back,
decreased food and water intake, and increased respiratory
rate) did not occur until about 20 hours later. The animals lost
an average of 9% of their bodyweight mainly due to dehydra-
tion. Two rats (one in the placebo group and one in the heparin
group) died shortly after intratracheal manipulation due to
laryngeal edema caused by the procedure. Rats sacrificed 40
hours after the bacterial challenge had evident bilateral macro-
scopic lung infiltrates.
Pulmonary coagulation and fibrinolysis
Bronchoalveolar levels of TATc were increased by pulmonary
infection (Figure 1). Rh-aPC, plasma-derived AT, heparin or
danaparoid all limited a pneumonia-induced rise of bronchoal-
veolar TATc (P < 0.01 versus placebo). FDP generation was
attenuated significantly by all anticoagulants (P < 0.01 versus
placebo) except for heparin (P = 0.26). AT activity seemed to
be increased after nebulization of rh-aPC, heparin or danapar-
oid, although the results were not statistically significant.
Administration of AT resulted in supranormal levels of AT (P <
0.01 versus placebo and P < 0.01 versus control). Pulmonary
PAA was significantly reduced with infection, with concur-
rently enhanced PAI-1 activity in lungs. Both rh-aPC and AT
attenuated enhanced PAI-1 activity (P < 0.01 versus placebo)
and AT treatment significantly increased bronchoalveolar PAA
(P < 0.01 versus placebo).
Systemic coagulation and fibrinolysis
Compared with healthy controls, challenge with S. pneumo-
niae caused increased plasma levels of TATc (Figure 2). This
was not affected by rh-aPC, plasma-derived AT and heparin.
Danaparoid, however, significantly reduced systemic TATc
levels (P < 0.01 versus placebo). Compared with controls,
plasma PAA was significantly decreased after intratracheal
challenge with bacteria. None of the treatments altered plasma
PAA.
Bacterial outgrowth from lungs
From BALF of rats treated with plasma-derived AT fewer S.
pneumoniae CFU were cultured (P < 0.05 versus placebo;
Figure 3). At 40 hours after intratracheal challenge with S.
pneumoniae, one of six (17%) placebo rats had bacteremia.
The proportion of bacteremia was not different in rats treatedPage 3 of 10
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Figure 1with rh-aPC or plasma-derived AT, in which two of seven rats
(28%) and one of seven rats (14%) developed bacteremia,
respectively. The incidence of bacteremia seemed higher,
although not statistically significant, in the heparin and dana-
paroid treated groups (three of seven rats (43%) and five of
seven rats (71%), respectively).
Inflammatory response
After being sacrificed, the weight of the rats' lungs was signif-
icantly higher in animals with pneumonia compared with
healthy controls (P < 0.01; Figure 4). No statistically differ-
ences in lung wet weight were observed between the different
treatment groups. Total protein concentrations in BALF of rats
treated with anticoagulant agents were consistently lower than
in rats treated with normal saline. Only differences between
Pulmonary coagulation and fibrinolysis. The effects of anticoagulants nebulized into the lungs of rats on levels of (a) thrombin-antithrombin com-
plexes (TATc), (b) antithrombin activity (AT), (c) fibrin degradation products (FDP), (d) plasminogen activator activity (PAA%), and (e) plasminogen 
activator inhibitor-1 (PAI-1) in bronchoalveolar lavage fluid (BALF), 40 hours after intra-tracheal bacterial challenge (Streptococcus pneumoniae, 
serotype 3, ATCC 6303). Dotted lines stipulate the normal values in healthy animals and untreated animals with pneumonia. Data represent mean ± 
standard deviation. * P < 0.01 vs. placebo. APC = recombinant-human activated protein C; AT = plasma = derived human antithrombin; Hep = 
heparin; Dan = danaparoid.
Figure 2
Systemic coagulation and fibrinolysis. The effects of anticoagulants nebulized into the lungs of rats on plasma levels of (a) thrombin-antithrombin 
complexes (TATc) and (b) systemic plasminogen activator activity (PAA), 40 hours after intra-tracheal bacterial challenge. Dotted lines stipulate the 
normal values in healthy animals and untreated animals with pneumonia. Data represent mean ± standard deviation. * P < 0.01 vs. placebo. APC = 
recombinant-human activated protein C; AT = plasma = derived human antithrombin; Hep = heparin; Dan = danaparoid.Page 4 of 10
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significance (P < 0.001 versus placebo; Figure 4). There was
an increase in total cell number in the lungs during pneumonia
caused by S. pneumoniae, mostly attributed to neutrophil
influx (Table 1). Plasma-derived AT treatment lead to a
decrease of total numbers of cells in the BALF, in particular to
fewer neutrophils. MPO activity was not affected by any treat-
ment except for heparin. Lung levels of TNF, IL-6, and CINC-3
were highly variable and there were no differences in pulmo-
nary levels between groups (Figure 5).
Histopathology
At 40 hours after induction of S. pneumoniae pneumonia, pul-
monary histopathology showed dense inflammatory infiltrates,
consisting predominantly of neutrophils, localized in the inter-
stitium, alveolar space, and bronchial lumina (Figure 6). Inter-
stitial inflammation, endothelialitis, bronchitis, and edema were
present to a variable extent. Only differences between plasma-
derived AT and saline treatment reached statistical signifi-
cance (P < 0.05).
Outgrowth of S. pneumoniae in BALF: effect of plasma-
derived AT
A decrease in bacterial outgrowth was observed when S.
pneumoniae was grown in BALF-AT samples compared with
BALF-none samples after five hours (Figure 7). Adding
plasma-derived AT to culture medium had no effect on out-
growth of S. pneumoniae in any concentration (i.e., for the
entire AT concentration range (0.017 to 4.4 mg/ml) similar
bacterial outgrowth curves were observed).
Bacterial numbers in BALF-AT in TSB medium were strongly
reduced after six hours compared with the start of the experi-
ment, which confirmed that BALF-AT had an antimicrobial
effect on S. pneumoniae. Adding SPS to the BALF-AT sam-
ples rescued the bacteria, because no decrease in CFU rela-
tive to the start of the experiment was seen after six hours.
Discussion
In this series of experiments we show local anticoagulant treat-
ment through nebulization of rh-aPC, plasma-derived AT,
heparin or danaparoid to attenuate pulmonary coagulopathy in
S. pneumoniae pneumonia in rats. Reduction of pulmonary
coagulopathy with nebulized rh-aPC, heparin or danaparoid
did not affect the course of pneumonia and ALI. However,
reduction of pulmonary coagulopathy with treatment plasma-
derived AT was associated with reduced bacterial outgrowth
and pulmonary inflammation in this model. Although local
administration of rh-aPC, plasma-derived AT or heparin did not
affect systemic thrombin generation, nebulized danaparoid
reduced systemic thrombin generation.
Figure 3
The effects of anticoagulants on numbers of Streptococcus pneumoniae colony forming units in (a) lung homogenate and (b) bronchoalveolar lavage fluid (BALF), 40 hours after intra-trach al bacterial challengeti l t   nu ers of Streptococcus pneumoniae colony forming units in (a) lung homogenate and (b) bronchoalveolar l v-
age fluid (BALF), 40 hours after intra-tracheal bacterial challenge. Data represent median ± interquartile range. * P < 0.05 vs. placebo. APC = 
recombinant-human activated protein C; AT = plasma = derived human antithrombin; CFU = colony-forming units; Hep = heparin; Dan = 
danaparoid.
Table 1
Total cell and neutrophil counts in bronchoalveolar lavage fluid
Total cells Neutrophils MPO
Controls 21 (19-24) 0 (0-0) 32 (20-59)
Streptococcus pneumoniae pneumonia (t = 40 hours)
Placebo 171 (92-206) 73 (39-112) 99 (53-106)
rh-aPC 208 (122-233) 86 (56-104) 186 (66-265)
AT 36 (23-38)* 1 (0-5)** 68 (24-74)
Heparin 417 (313-579) 92 (69-114) 498 (224-932)*
Danaparoid 542 (462-681) 111 (99-125) 407 (167-535)
Cell counts 40 hours after bacterial challenge (Streptococcus 
pneumoniae, serotype 3, ATCC 6303). Controls are uninfected rats 
(n = 4). Total cell and neutrophil data are expressed as median 
(interquartile range) × 104 per milliliter of bronchoalveolar lavage 
fluid. Myeloperoxidase (MPO) is expressed as pg/mL lung 
homogenate median (interquartile range). (* P < 0.05;** P < 0.01 
versus placebo according to Kruskal-Wallis and Dunn's post-tests).
rh-aPC = recombinant human activated protein C; AT = 
antithrombin.Page 5 of 10
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Of the investigated nebulized anticoagulant agents only
plasma-derived AT treatment resulted in significant lung-pro-
tective effects, with less bacterial outgrowth and less his-
topathological changes. This finding confirms earlier results
with systemically administered plasma-derived AT in the same
model [1]. AT is one of the major physiologic inhibitors of
coagulation, capable of inactivating thrombin and factors Xa,
IXa, and VIIa bound to tissue factor [24]. Severe inflammatory
processes result in increased consumption of AT [25]. In a
small group of sepsis patients, AT treatment improved lung
function [14]. In a larger phase III trial with sepsis patients, AT
treatment reduced the prevalence of new pulmonary dysfunc-
tion, but patient outcome was unchanged [14]. Unfortunately,
outcome of preexistent respiratory failure was neither
assessed nor reported.
AT may exert its protective effects through increased prosta-
cyclin-mediated inhibition of cytokines, decreased nuclear fac-
tor-kB activation [26], and consequent inhibition of leukocyte
activation and migration [27-30]. AT may compete with bacte-
rial toxins for binding on endothelial cell proteoglycans [31],
limiting the inflammatory response after bacterial challenge
and thereby limiting cell and neutrophil influx into the pulmo-
nary department [32]. Here we show that plasma-derived AT
treatment strongly inhibited bacterial outgrowth consequently
limiting inflammatory response, neutrophil influx and his-
topathological changes. It remains unclear whether these
effects are associated with prostacyclin formation, interfer-
ence with bacterial toxins (e.g., pneumolysin), or reduced inhi-
bition of antimicrobial peptides (e.g., defensins) through
reduced levels of extracellular proteins and coagulation prod-
ucts but at least it is most likely that there are processes
involved that are independent of anticoagulant activity. Addi-
tional research is needed to elucidate the mechanisms by
which plasma-derived AT affects bacterial outgrowth, inflam-
matory response and migration of neutrophils into the pulmo-
nary compartment.
Figure 4
Lung wet weights (a) and total protein levels in (b) bronchoalveolar lavage fluid (BALF), 40 hours after intra-tracheal bacterial challengei i l l  i  ( ) r l l r l v  fluid ( ALF), 40 hours after intra-tracheal bacterial challenge. Dotted lines 
stipulate the normal values in healthy animals and untreated animals with pneumonia. Data represent median ± interquartile range. * P < 0.01 vs. pla-
cebo. APC = recombinant-human activated protein C; AT = plasma = derived human antithrombin; Hep = heparin; Dan = danaparoid.
Figure 5
(a) TNF-α, (b) IL-6, and (c) cytokine-induced neutrophil chemoattractant (CINC)-3, determined in lung homogenates 40 hours after intra-tracheal bacterial challenge - , ( ) IL-6, and (c) cytokine-induced neutrophil chemoa tractant (CINC)-3, determined in lung homogenates 40 hours after intra-tracheal 
bacterial challenge. Dotted lines stipulate the normal values in healthy animals and untreated animals with pneumonia. Data represent median ± 
interquartile range. APC = recombinant-human activated protein C; AT = plasma-derived human antithrombin; Hep = heparin; Dan = danaparoid.Page 6 of 10
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benefit patients with S. pneumoniae pneumonia, but
additional pre-clinical studies are needed to examine this
hypothesis before this therapy is to be tested in patients. The
coagulation system plays an important role in containing infec-
tions and certain microorganisms even induce profibrinolytic
mechanisms to escape from being contained in a fibrin clot
[33]. Coagulation and inflammation are pivotal host defence
mechanisms, and interference with these pathways should be
performed with great care because this may also have delete-
rious effects. Indeed, previous preclinical studies have demon-
strated interfering with the initial procoagulant response in
Pseudomonas aeruginosa pneumonia in rats and mice is
potentially dangerous [34,35].
Figure 6
Histopathological changes in Streptococcus pneumoniae pneumonia. Shown are representative hematoxylin and eosin-stained photomicrographs 
(magnification, ×100) of lung tissue from rats treated with (a) saline, (b) recombinant human activated protein C (APC), (c) plasma-derived anti-
thrombin (AT), (d) heparin (Hep), (e) danaparoid (Dan), at 40 hours after bacterial challenge. (f) Total histopathologic scores are presented as 
median with interquartile range. * P < 0.05 vs. placebo.
Figure 7
The effects of BALF from placebo treated rats (BALF-none) and BALF from rats treated with plasma-derived AT (BALF-AT) on survival of Strepto-coccus pneumoniae in vitro
coccus pneumoniae in vitro. (a) After five hours outgrowth of S. pneumoniae in bronchoalveolar lavage fluid from rats treated with plasma-derived 
antithrombin (BALF-AT) was reduced (closed symbols), compared with the outgrowth in BALF-none samples (open symbols). * P < 0.0001 vs. 
BALF-AT. (b) In vitro added plasma-derived AT did not affect the number of colony-forming units (CFU; for clarity only the highest concentrations are 
shown: 1.1 mg/mL, open symbols; 4.4 mg/mL, closed symbols). (c) Sodium polyanetholsulphonate (SPS) blocked the inhibitory effect of BALF-AT 
on outgrowth of S. pneumoniae (BALF-AT without SPS, closed symbols; BALF-AT with SPS, open symbols). Data represent mean ± standard devi-
ation. * P < 0.0001 vs. BALF-AT without SPS.Page 7 of 10
(page number not for citation purposes)
Critical Care    Vol 13 No 5    Hofstra et al.Systemic anticoagulant affects of nebulized 
anticoagulants
Systemic administration of anticoagulant compounds substan-
tially increases the risk of bleeding. In the clinical trial with rh-
aPC in patients with severe sepsis, the incidence of serious
bleeding was higher in the treatment group than in the placebo
group (3.5% versus 2.0%) [9]. In a randomized controlled trial
with AT the occurrence of bleeding events in patients with
severe sepsis was even more pronounced, especially when AT
was combined with heparin (22.0% versus 12.8%) [15]. In the
present study with inhaled anticoagulants, none of the investi-
gated agents, with the exception of danaparoid, affected sys-
temic coagulation suggesting inhaled anticoagulants may
reduce the risk of systemic bleeding.
The systemic effects on coagulation of nebulized danaparoid
suggest that this agent is leaking from the pulmonary compart-
ment into the circulation after local administration. Danaparoid
is a relatively small molecule of 5.5 kDa which is more likely to
leak into the circulation as compared with rh-aPC (56 kDa) or
plasma-derived AT (58 kDa). Heparin is also a small molecule
(8 kDa); however, it did not seem to leak into the circulation in
our experiments. This may be due to binding of heparin to pul-
monary endothelial cells and alveolar proteins and metabolism
by heparinases [36]. A recent clinical study of nebulized
heparin in patients with ALI; however, did show systemic
effects in the highest concentration used [37], although this
dose was up to 40% higher than the dose we used in our ani-
mal study.
Previous studies on anticoagulant strategies for 
pneumonia
Our results are in line with data from previous animal studies.
With the same model we previously showed that systemic
administration of rh-aPC, plasma-derived AT or heparin altered
bronchoalveolar coagulation [1]. In that study systemically
administered heparin, however, did not alter pulmonary coag-
ulopathy. Here we show that all nebulized agents limit pulmo-
nary coagulopathy to a similar extent.
rh-aPC exerts profibrinolytic effects through inactivation of
PAI-1 [38]. In our experiments reduction of PAI-1 activity in the
rh-aPC-treated rats was, however, not sufficient to influence
bronchoalveolar PAA. Interestingly, plasma-derived AT
affected PAI-1 activity, as well as bronchoalveolar PAA. To our
knowledge, no direct effects of AT have been described that
account for such alterations in these fibrinolytic markers. It is
possible that these changes are due to the reduction in bacte-
rial load observed in the plasma-derived AT-treated rats.
In vitro experiments
The in vitro experiments confirmed, at least in part, the findings
of the in vivo animal study. Indeed, bacterial outgrowth in
BALF from rats treated with plasma-derived AT was reduced
when compared with BALF from placebo-treated animals. Our
experiment with TSB medium with different concentrations of
plasma-derived AT showed this was not caused by a direct
antibacterial effect of AT. During infection, innate host immune
responses can lead to the expression of cationic antimicrobial
peptides [23]. Such peptides can be inhibited by nonspecific
binding to negatively charged parts of molecules such as
coagulation products and other extracellular proteins. We
hypothesize that the reduced bacterial outgrowth seen in our
in vivo experiments might have been due to the fact that
plasma-derived AT reduced total protein levels in the BALF by
a factor of 10 compared with placebo-treated rats, thereby
reducing the nonspecific inhibitory effects on cationic antimi-
crobial peptides. Neutralizing these cationic antimicrobial pep-
tides with SPS then should attenuate the possible inhibitory
effect of BALF-AT on S. pneumoniae. Indeed adding SPS to
BALF-AT diminished its inhibitory effect on the outgrowth of S.
pneumoniae after six hours. This finding implies that the induc-
tion of coagulation by S. pneumoniae serves to protect the
bacteria against cationic antimicrobial components, most likely
innate host defense peptides, and thus can be considered a
novel virulence mechanism. However, because the present
study treatment with rh-aPC resulted in quite similar anticoag-
ulant and profibrinolytic effects, while at the same time not
affecting bacterial outgrowth or ALI, other mechanisms than
anticoagulation may be responsible for the effects of plasma-
derived AT found. Details of these mechanisms are presently
under investigation.
Limitations
Our animal study has some important limitations. First, the
chosen dosages for each anticoagulant agent are determined
based on data from previous studies and pilot studies com-
bined with the efficacy of our nose-only exposure system, and
possibility of dissolving each agent to an acceptable volume
for nebulization. Although for all studied agents this approach
lead to a significant attenuation of pulmonary coagulopathy,
lower dosages may also have been sufficient. However, in
order to achieve anti-inflammatory effects higher doses of
these agents may be required than required for anticoagulant
use.
Second, due to differences between the studied drugs aero-
sol characteristics may differ between the treatment groups.
Third, in our study the agents were first administered before
induction of pneumonia. Pre-treatment models are useful
when exploring novel approaches and mechanisms, post-
treatment models more closely resemble the clinical situation.
The fact that the animals were treated intermittently in 6- or 24-
hour intervals is another limitation to our study. Although this
limited bronchoalveolar coagulation, continuous administra-
tion may have been more effective in order to achieve anti-
inflammatory effects. Also, during nebulization the rats may
have ingested some of the medication. Plasma-derived AT and
rh-aPC are most likely to be inactivated immediately by gastricPage 8 of 10
(page number not for citation purposes)
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digestive tract in small quantities [39]. During each nebuliza-
tion the animals were exposed to a constant oxygen flow (2 L/
min) for a period of 10 minutes. The difference in treatment fre-
quency between the AT-treated animals and the other groups
therefore lead to a difference in exposure to oxygen, which in
turn may have affected bacterial outgrowth as demonstrated
previously [40]. This oxygen effect, however, cannot, explain
the persistant inhibition of bacterial growth in vitro.
Another limitation of the study is inherent to the fact that our
rat model of pneumonia at best mimics the clinical situation. In
our model healthy animals of the same sex, age and weight are
challenged with a high dose of viable log-phase bacteria
inducing pneumonia over a short period of time in a reproduc-
ible manner, and clinical factors, such as antimicrobial therapy,
mechanical ventilation, fluid management and other supportive
interventions are not accounted for. Despite the limitations of
our model, our results are in line with previous investigations
[1].
Although the incidence of bacteremia was higher in the
heparin- and danaparoid-treated groups statistical signifi-
cance was not reached. Our study, however, may have been
underpowered to detect effects on bacterial dissemination.
A limitation of our in vitro investigation is that S. pneumoniae
has a different behavior in vitro compared with in vivo. For
example, bacteria have been observed to reach competence
(i.e. obtain the ability to kill their non-competent siblings) in rich
medium in vitro in early logarithmic growth, which is not seen
in vivo, where nutrients are generally limited [41,42]. As the
peptide which induces competence, competence stimulating
peptide, is cationic, it is not unthinkable that its normal activity
is altered or diminished in the presence of SPS in our in vitro
experiments. This altered or impaired activity of competence
stimulating peptide or other cationic signaling molecules might
result in a change in the growth curve observed for S.
pneumoniae.
Conclusions
In conclusion, pulmonary coagulopathy with pneumonia may
allow for interventions aimed at local administration of antico-
agulant agents. The effects of rh-aPC, plasma-derived AT and
heparin were restricted to the pulmonary compartment, neb-
ulized danaparoid also affected systemic coagulation. AT has
a lung-protective effect which seems to be related, at least in
part, to an indirect role in reduction of bacterial outgrowth of
S. pneumoniae.
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